Throughout the last three months, 8 analysts have evaluated Humana (NYSE:HUM), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 0 | 6 | 1 | 0 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 0 | 0 | 2 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 3 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $254.25, a high estimate of $313.00, and a low estimate of $174.00. This current average represents a 2.26% decrease from the previous average price target of $260.14.
Breaking Down Analyst Ratings: A Detailed Examination
An in-depth analysis of recent analyst actions unveils how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Erin Wright | Morgan Stanley | Lowers | Underweight | $174.00 | $262.00 |
| Stephen Baxter | Wells Fargo | Announces | Equal-Weight | $290.00 | - |
| Andrew Mok | Barclays | Raises | Equal-Weight | $245.00 | $234.00 |
| Erin Wright | Morgan Stanley | Lowers | Equal-Weight | $262.00 | $277.00 |
| David Windley | Jefferies | Raises | Buy | $313.00 | $253.00 |
| Andrew Mok | Barclays | Lowers | Equal-Weight | $234.00 | $245.00 |
| David Macdonald | Truist Securities | Lowers | Hold | $285.00 | $300.00 |
| George Hill | Deutsche Bank | Lowers | Hold | $231.00 | $250.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Humana. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Humana compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Humana's stock. This analysis reveals shifts in analysts' expectations over time.
Capture valuable insights into Humana's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Humana analyst ratings.
Get to Know Humana Better
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Key Indicators: Humana's Financial Health
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Humana's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 11.06%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Humana's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 0.6%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Humana's ROE excels beyond industry benchmarks, reaching 1.06%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Humana's ROA excels beyond industry benchmarks, reaching 0.39%. This signifies efficient management of assets and strong financial health.
Debt Management: Humana's debt-to-equity ratio is below the industry average. With a ratio of 0.68, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.